A Phase 2a Study to Evaluate the Safety and Tolerability of Two Repeated Doses of GM-2505 at a 2-Week Interval in Patients With Major Depressive Disorder.
Latest Information Update: 14 Mar 2024
At a glance
- Drugs GM 2505 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Gilgamesh Pharmaceuticals
- 06 Mar 2024 Status changed from not yet recruiting to recruiting.
- 30 Jan 2024 Status changed from planning to not yet recruiting.
- 04 Dec 2023 New trial record